Tandem Approval Brings GSK’s Tafinlar And Mekinist To A Market Ready To Test Combinations
This article was originally published in The Pink Sheet Daily
Executive Summary
Glaxo’s BRAF inhibitor dabrafenib and MEK inhibitor trametinib were approved as single agents for advanced melanoma, but the real promise lies in combination therapy for better efficacy and safety. Labeling for trametinib notes it is not indicated in patients who have already received BRAF therapy.
You may also be interested in...
Keeping Track: Pre-Independence Day Fireworks Crackle At US FDA With Burst Of Approvals And Filings
The latest drug development news and highlights from our US FDA Performance Tracker.
Doubling Down: Merck Serono Inks Second Oncology Deal With Chinese Biotech BeiGene
German drug maker Merck Serono inked its second global licensing, co-development and commercialization deal this year with Chinese biotech BeiGene. During a signing ceremony in Beijing, execs from both companies talked about their development strategy.
Doubling Down: Merck Serono Inks Second Oncology Deal With Chinese Biotech BeiGene
German drug maker Merck Serono inked its second global licensing, co-development and commercialization deal this year with Chinese biotech BeiGene. During a signing ceremony in Beijing, execs from both companies talked about their development strategy.